Strategic management of innovation risk in the biopharmaceutical industry: a UK perspective Online publication date: Mon, 30-Jun-2003
by C.R. Chandrasekar, C.V. Helliar, A.A. Lonie, W.A. Nixon, D.M. Power
International Journal of Healthcare Technology and Management (IJHTM), Vol. 1, No. 1/2, 1999
Abstract: This paper explores whether that part of the strategic management literature that is concerned with innovation risk may help our understanding of changes in the UK biopharmaceutical industry. In particular, the changes in this industry are analysed to determine whether companies now take account of the real options embedded in their drug development process and include these options in their evaluation of research and development expenditures. In addition, the paper considers whether advances in the management of risks associated with new technology are being applied in the biopharmaceutical sector. A pilot case study of one firm in this industry is examined and the results of three interviews discussed. The principal finding of this study is that a firm which has adopted leading-edge techniques advocated in the recent literature on the subject has achieved remarkable technical and economic success.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Healthcare Technology and Management (IJHTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook